Clinical Trials

29 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT07092514 2026-03-17

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Other hematologic neoplasm

34 enrolled

Head & Neck

Thyroid Neoplasms

NCT03486873 2026-03-16

MK-3475-587

Phase 3 Recruiting

3,500 enrolled

Hematologic Neoplasms

NCT04164199 2026-03-16

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Enrolling by invitation

430 enrolled

Advanced Malignancies

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05523323 2026-03-13

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Phase 3 Completed

112 enrolled 16 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

30 enrolled

Uterine Cervical Neoplasms

NCT05824481 2026-03-10

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

32 enrolled

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT07460206 2026-03-10

PRELUDE

108 enrolled

Carcinoma, Renal Cell

NCT06859684 2026-03-09

HAIC-quad

25 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT03573960 2026-03-06

A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Phase 4 Completed

50 enrolled

Head & Neck

Thyroid Neoplasms

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

90 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06114940 2026-03-05

PLUTO

Phase 2 Terminated

17 enrolled

Carcinoma, Renal Cell

NCT06253494 2026-03-03

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

60 enrolled

Endometrial Neoplasms

NCT05319730 2026-03-02

MK-3475-06B

230 enrolled

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04008797 2026-02-27

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

301 enrolled

GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04321954 2026-02-27

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Phase 2 Not yet recruiting

30 enrolled

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

30 enrolled

Cholangiocarcinoma

NCT05603910 2026-02-24

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Phase 1 Recruiting

18 enrolled

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 1 FDA

Phase 3 Active not recruiting

Carcinoma, Renal Cell

NCT04039607 2026-02-19

CheckMate 9DW

732 enrolled 1 FDA

Carcinoma, Hepatocellular

NCT05775159 2026-02-18

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

294 enrolled

Phase 2 Not yet recruiting

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

60 enrolled

Other solid neoplasm

Solid Tumors

NCT07417800 2026-02-18

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

Phase NA Not yet recruiting

1,000 enrolled

Carcinoma, Hepatocellular

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT06669572 2026-02-17

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment